Photothermal-sensitive biomimetic liposomes coated with DOX and IR820 for chemo-photothermal-photodynamic therapy of cancer in lung cancer cells
10.16438/j.0513-4870.2023-1087
- VernacularTitle:肺癌细胞膜涂层的DOX和IR820的光热敏感型仿生脂质体用于癌症的化学-光热-光动力治疗
- Author:
Shi-zhuang LI
1
;
Yu-ping KAN
1
;
Ming CHEN
2
;
Hui SU
1
;
Xue-ying YAN
1
Author Information
1. Heilongjiang University of Traditional Chinese Medicine, Harbin 150040, China
2. Harbin 242 Hospital, Harbin 150040, China
- Publication Type:Research Article
- Keywords:
photothermal sensitive liposome;
cancer cell membrane biomimetic;
new indocyanine green;
chemotherapy-photothermal therapy-photodynamic therapy
- From:
Acta Pharmaceutica Sinica
2024;59(5):1430-1440
- CountryChina
- Language:Chinese
-
Abstract:
In this study, doxorubicin (DOX) was used as the model drug, new indocyanine green (IR820) as the photosensitizer, and temperature sensitive liposomes (TSL) as the carrier. H460-NCI photoheat-sensitive liposomes coated with cell membrane of human cell lung cancer (DOX-IR820-TSL@CCM) for highly effective multi-pathway tumor targeting in chemical-photothermal therapy and photodynamic therapy. DOX-IR820-TSL was prepared by reverse evaporation, cancer cell membrane (CCM) was prepared by lysis, crushing and centrifugation, and DOX-IR820-TSL@CCM was prepared by nanomembrane extrusion. The drug-loading conditions of DOX-IR820-TSL were finally determined: the ratio of organic phase to aqueous phase was 4.02, the dosage of dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was 10.04 mg, and the lipid ratio was 0.12, and the significant phase transition temperature (Tm) of DOX-IR820-TSL was 43.05 ℃. The average particle size of DOX-IR820-TSL@CCM was 153.4 nm, the PDI was 0.279, and the zeta potential was -26.2 mV. The transmission electron microscope (TEM) image shows a homogeneous spherical structure and a translucent film layer. Under near-infrared irradiation, the drug release rate reaches 63.98%, which has adjustable photothermal conversion capacity and the ability to generate reactive oxygen species. Through SDS-PAGE electrophoresis, Western blot, cytotoxicity experiments and cell uptake experiments, it was proved that the design of cell membrane coating can well retain CD47, N-cadherin, CD44, CD326 and other related functional proteins, so that DOX-IR820-TSL@CCM has good immune evasion, homologous adhesion and homologous targeting. In this paper, DOX-IR820-TSL@CCM with camouflage properties and tumor targeting properties were successfully prepared, which can be used as a promising synergistic therapeutic diagnostic platform for future lung cancer treatment. All animal research programs have been approved by the Animal Ethics Committee of Heilongjiang University of Chinese Medicine (number: 2022121011).
